Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I

Published:2010-01 Issue:1 Volume:13 Page:3-7
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Hay Joel W.,Smeeding Jim,Carroll Norman V.,Drummond Michael,Garrison Louis P.,Mansley Edward C.,Mullins C. Daniel,Mycka Jack M.,Seal Brian,Shi Lizheng

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference22 articles.

1. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices—budget impact analysis;Mauskopf;Value Health,2007

2. Principles of good practice for decision analytic modeling in health care evaluation: report of the ISPOR Task Force on good research practices—modeling studies;Weinstein;Value Health,2003

3. Good research practices for cost-effectiveness alongside clinical trials: the ISPOR RCT-CEA Task Force report;Ramsey;Value Health,2005

4. Application of cost effectiveness and cost benefit analysis to pharmaceuticals;Hay,2006

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of the perspectives used in health economic evaluations;Cost Effectiveness and Resource Allocation;2024-05-14

2. The Checklist for Standard Methodological Requirements and Reporting of Economic Evaluation of Medicines in Slovakia;Value in Health Regional Issues;2024-01

3. The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA;Journal of Comparative Effectiveness Research;2023-10

4. Pricing New Drugs for COVID-19 in the Pharmaceutical Industry: Insights From the Chinese Medical Insurance;International Journal of Health Policy and Management;2023-06-18

5. The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses of Biologics;Value in Health;2023-03